MacroGenics (NASDAQ: MGNX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
MacroGenics Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
MacroGenics Company Info
News & Analysis
The company had quite a comedown shortly after releasing its latest set of annual results.
The cancer-focused biotech delivered a strong earnings report.
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.
Profit-taking and an analyst downgrade affected the stock's price.
Positive momentum continues for the cancer specialist in the wake of its latest earnings report.
Investors and analysts alike are getting more bullish on the company in the wake of its third-quarter results.
A quarter that was far better than expected gets investors excited about the biotech at the end of the week.
An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.
MGNX earnings call for the period ending December 31, 2022.
MGNX earnings call for the period ending September 30, 2022.
MGNX earnings call for the period ending June 30, 2022.
MGNX earnings call for the period ending December 31, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.